NEURACAP
Sector OutlookPublished · 22 pages · Free to read

Pharmaceuticals Sector Outlook — September 2026

This report maps pharmaceuticals by business model, valuation and precedent transactions, showing where earnings durability supports premium pricing. Built for owners, management teams and boards assessing portfolio strategy, exclusivity risk and cost-structure resilience.

For information only. Not an appraisal or a fairness opinion.

What moved since: Pharmaceuticals M&A update, 14–28 September 2026

Key figures

Sector median valuation
11.6x
P/E (CY2027E), rated companies
Premium tier P/E
21.4x
Top of the rated P/E (CY2027E) range
Discount tier P/E
7.1x
Bottom of the rated P/E (CY2027E) range
Higher-margin cohort P/E
15.3x
Above 30% EBITDA margin, vs 9.9x below

Read the report

NeuraCap

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › PHARMACEUTICALS

Pharmaceuticals: The Premium Sits with Durability

This report shows how earnings durability, business model and asset risk sit alongside valuation across the peer set.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis P / E (CY2027E)

Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice

1

1 / 22

Executive summary

Across the rated pharmaceuticals peer set, the premium end of the P/E (CY2027E) range trades at 21.4x versus 7.1x at the discount end, a gap associated with earnings durability rather than faster growth. Business model — diversified majors, development-stage therapeutics and specialty manufacturers — shapes this positioning more than any single growth or margin metric. Precedent transactions show pricing also moves with asset type and earnings visibility. The evidence points owners and boards toward protecting exclusivity runway and cost-structure resilience.

Key findings

  • Valuation premium tracks earnings durability more than near-term growth
  • Diversified majors, developers and specialty manufacturers need different lenses
  • Only two rated companies clear both growth and margin bars together
  • Deal pricing shifts with asset type and earnings certainty at announcement

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › PHARMACEUTICALS

    This is the cover slide for NeuraCap's Pharmaceuticals sector outlook, dated September 2026.

    We open with the sector's core finding: valuation premium in pharmaceuticals tracks earnings durability, not near-term growth. Everything that follows in this report builds the evidence behind that line.

    Everything on this page

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › PHARMACEUTICALS Pharmaceuticals: The Premium Sits with Durability This report shows how earnings durability, business model and asset risk sit alongside valuation across the peer set. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis P / E (CY2027E) Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    This slide lists the report's five sections plus the appendix.

    We walk through five sections plus an appendix, starting with the bottom line so a client who only reads section one still gets the full argument. Then we build out the landscape, valuation and situations, precedent transactions and strategic implications in order. This structure lets us front-load the conclusion and use the rest of the deck to substantiate it, so a client's time is never wasted.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Durable Earnings Separate the Pricing Tiers 02 The Landscape One Sector Contains Three Distinct Earnings Models 03 Valuation & Situations The Premium Survives a Forward Earnings Lens 04 Precedent Transactions Precedent Transactions Reward Different Forms of Certainty 05 Strategic Implications Durability Must Be Built into the Earnings Base 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Pharmaceuticals Split into Diversified Majors, Development-Stage Therapeutics and Specialty Manufacturers

    This slide summarizes how pharmaceuticals split into diversified majors, development-stage therapeutics and specialty manufacturers.

    We price this sector on P/E (CY2027E), the practitioner-standard basis, with 13 of the 21 companies in our universe eligible for a rated multiple. That coverage is deep enough to hold as the sector standard, so every comparison on this page rests on a like-for-like earnings basis. The split into diversified majors, development-stage therapeutics and specialty manufacturers is the frame that makes every valuation comparison meaningful, so what follows never blends businesses that don't compete for the same capital.

    Everything on this page

    01 · THE BOTTOM LINE Pharmaceuticals Split into Diversified Majors, Development-Stage Therapeutics and Specialty Manufacturers The full story on one page · figures on P / E (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: P / E on CY2027E consensus (13 of 21 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on P / E rather than EV / EBITDA; validated coverage supports the industry standard (13 of 21 companies), so this report follows it. Qualitative characterisations are NeuraCap views. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Top of the Pricing Range Is Associated with More Durable Earnings The premium end of the 13 names with a forward estimate is priced at 21.4x, versus 7.1x at the discount end. Because the forward P / E lens already credits forecast earnings, the remaining gap is associated with confidence in how long those earnings can hold. 2 Faster Growth Does Not Sit with the Higher-Priced Group Among the 13 names with a forward estimate, the 7 faster-growing names are priced at 10.0x, while the 6 slower-growing names are priced at 15.3x. The result points owners toward exclusivity runway, replacement capacity and earnings quality when testing market standing. 3 Business Model Comes Before Peer Selection Diversified branded pharmaceutical majors and development-stage novel therapeutics represent 38% apiece, while specialty branded and generic manufacturers represent 24%. Their different exposure to product maturity, financing needs and loss of exclusivity makes a blended sector comparison less informative. 4 Balanced Operating Performance Is Uncommon in the Measured Set Across the 12 names with growth and margin data, 2 clear both operating bars and are priced at 18.8x. Johnson & Johnson (JNJ) and AbbVie Inc. (ABBV) occupy that position, pairing growth with established profitability. 11.6x Sector median P/E CY2027E consensus · 13 rated of 21 companies 21.4x Premium end P/E vs 7.1x at the discount end top quartile (n=3) against bottom quartile (n=3) on P/E — the spread the report explains 14 Transactions with disclosed terms 31 recorded in this tier · 1 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    This is a section divider introducing the market landscape across three pharmaceutical business models.

    We reset here before showing how enterprise value sits across three distinct earnings models. Diversified majors, development-stage therapeutics and specialty manufacturers each need their own valuation frame.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE One Sector Contains Three Distinct Earnings Models Diversified majors, development-stage therapeutics and specialty manufacturers require different valuation frames. 02 of 06 Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Enterprise Value Sits Across Three Different Pharmaceutical Models

    This slide groups 21 approved companies by business segment and shows median P/E (CY2027E) per group.

    We group the approved companies into three business segments and show the median P/E (CY2027E) each segment carries. The grouping follows our platform's classification, so group medians only reflect rated names within each segment. Segment identity, not sector averages, is the first filter for reading value in this space, so a client should anchor every comparison to segment before multiple.

    Everything on this page

    02 · MARKET MAP Enterprise Value Sits Across Three Different Pharmaceutical Models 21 approved companies grouped by business segment · median P / E (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 DIVERSIFIED BRANDED PHARMACEUTICAL MAJORS 8 cos median 15.3x Johnson & Johnson (JNJ) AbbVie (ABBV) Merck & Co. (MRK) Novartis (NVS) Pfizer (PFE) Sanofi (SNY) Grifols, S.A. (GRFS) Organon & (OGN) Cash-generative portfolios are judged on earnings durability across the exclusivity cycle and the capacity to replace revenue. DEVELOPMENT-STAGE NOVEL THERAPEUTICS 8 cos median 10.5x Disc Medicine (IRON) Phathom (PHAT) Design (DSGN) Fennec (FENC) BioAge Labs (BIOA) Fortress Biotech (FBIO) LENZ Therapeutics (LENZ) Pliant (PLRX) Asset quality, regulatory progress and cash runway matter more than current earnings for much of this group. SPECIALTY BRANDED AND GENERIC MANUFACTURERS 5 cos median 10.0x Elanco Animal (ELAN) Alkermes (ALKS) Supernus (SUPN) Phibro Animal (PAHC) ANI (ANIP) Focused portfolios bring product concentration, payer execution and manufacturing economics into sharper view.

  6. 06
    02 · LANDSCAPE

    Whether a Company Looks Cheap or Expensive Depends on Which Peers It Sits Beside

    This slide gives a segment-level view of the rated universe using P/E (CY2027E) medians.

    We show how a company's valuation reads differently depending on which segment peers surround it. Segment medians use only the rated names in each group, keeping every comparison like-for-like on P/E (CY2027E). Full company-level detail sits in the appendix, so this page focuses the argument at the segment level: where a company sits in this report changes what 'cheap' or 'expensive' means, so peer selection is the first decision, not the last.

    Everything on this page

    02 · LANDSCAPE Whether a Company Looks Cheap or Expensive Depends on Which Peers It Sits Beside Segment view of the approved universe · P / E (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median P/E Names to know What they do — and why it matters Diversified branded pharmaceutical majors 8 38% 15.3x Johnson & Johnson (JNJ) · AbbVie Inc. (ABBV) · +6 more Durability anchors the story. These businesses combine established earnings with recurring exposure to the patent cliff. Portfolio replacement, lifecycle management and remaining exclusivity runway frame the market view. Development-stage novel therapeutics 8 38% 10.5x Disc Medicine, Inc. (IRON) · Phathom Pharmaceuticals, Inc. (PHAT) · +6 more Asset proof comes first. Many names are still building toward repeatable earnings. Clinical evidence, regulatory timing, financing needs and the payer path therefore carry greater weight. Specialty branded and generic manufacturers 5 24% 10.0x Elanco Animal Health Incorporated (ELAN) · Alkermes plc (ALKS) · +3 more Focus sharpens execution risk. These companies concentrate value in narrower portfolios. Gross-to-net performance, formulary access, supply reliability and product concentration can materially change the earnings profile.

  7. 07
    SECTION 03

    03

    This is a section divider introducing the forward-earnings valuation analysis.

    We move next into testing whether the sector's premium survives a forward earnings lens. The two ends of the range point to different views of how durable those earnings are.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Premium Survives a Forward Earnings Lens The two ends of the range point to different views of earnings durability. 03 of 06 Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    The Premium End Prices a More Durable Earnings Base

    This slide sorts all 13 rated companies by P/E (CY2027E) against a sector median of 11.6x.

    We sort all 13 rated companies by P/E (CY2027E) against a sector median of 11.6x, splitting the range into tier zones cut at the rated set's quartiles. Every multiple on this page sits on the same forward-earnings basis, so the spread is not an artifact of mixing valuation methods. The premium end of that range prices in a more durable earnings base, so the question for any name is where its own earnings visibility places it.

    Everything on this page

    03 · PUBLIC MARKET VALUATION The Premium End Prices a More Durable Earnings Base P / E (CY2027E) · all 13 rated companies, sorted descending · sector median 11.6x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: P / E on CY2027E consensus (13 of 21 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on P / E rather than EV / EBITDA; validated coverage supports the industry standard (13 of 21 companies), so this report follows it. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same P / E (CY2027E) basis. Panel commentary is a NeuraCap view. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 21.4x CORE · median 11.6x DISCOUNT · median 7.1x Sector median 11.6x WHAT SEPARATES THE TWO ENDS The gap remains forward. The premium tier is priced at 21.4x, versus 7.1x for the discount tier. A forward P / E lens already incorporates forecast earnings, so the surviving spread is associated with confidence beyond the forecast period. Portfolio shape matters. The premium end includes diversified and specialty models. The discount end includes development-stage, specialty and diversified names, showing that the sector label alone does not define standing. Durability needs operating proof. Remaining exclusivity, replacement capacity, payer access and gross-to-net discipline provide the practical tests behind confidence in future earnings.

  9. 09
    03 · VALUATION DRIVERS

    Profitability Separates the Two Ends: Names Above the 30% Margin Line Carry 15.3x Against 9.9x Below It

    This slide compares median P/E (CY2027E) across revenue-growth and EBITDA-margin cohorts.

    We split the rated set at its own covered medians for growth and margin and compare the resulting P/E (CY2027E) medians. Names above the 30% margin line carry 15.3x against 9.9x below it, while the growth cut tells a different story entirely. Profitability, not growth, is the variable most associated with pricing here, so margin durability deserves more weight than top-line pace when testing a company's standing.

    Everything on this page

    03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 30% Margin Line Carry 15.3x Against 9.9x Below It Median P / E (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=7; slower n=6; higher-margin n=6; lower-margin n=6). Driver readings are NeuraCap views on the supplied data — association, not causation. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 P/E, median per cohort · growth split at 7% · EBITDA-margin split at 30% The Growth Split Runs Against a Simple Momentum Story On the 13 names with a forward estimate, the 7 names above the 7% growth split are priced at 10.0x, while the 6 names below it are priced at 15.3x. The observed premium therefore sits with the slower-growing group. Exclusivity Changes the Quality of Reported Growth Growth backed by remaining exclusivity, formulary access and repeatable patient demand has a different risk profile from growth facing near-term loss of exclusivity or heavy gross-to-net pressure. Replacement Capacity Matters Beyond the Forecast A forward multiple already reflects expected earnings. Pipeline depth, label expansion and lifecycle management can help distinguish a forecast that extends from one that depends on a narrow product base.

  10. 10
    03 · SITUATION MAP

    Growth Momentum and Valuation Support Sit with Different Groups of Names

    This slide maps rated companies by P/E versus the sector median and revenue growth versus the covered median.

    We cut the rated universe on P/E against the sector median of 11.6x and on revenue growth against the covered median of 7%, producing four situations rather than a single ranking. This is an observational map, not a recommendation, so each quadrant simply names where a company currently sits on growth and pricing. Where a company lands here frames the questions worth asking next, so we use it as the bridge into the strategic agenda.

    Everything on this page

    03 · SITUATION MAP Growth Momentum and Valuation Support Sit with Different Groups of Names Cut on P / E vs the sector median (11.6x) (rows) and revenue growth vs the covered median (7%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Growth with Premium Standing Above-median multiple · above-median revenue growth 3 names Johnson & Johnson (JNJ) · AbbVie Inc. (ABBV) · Fennec Pharmaceuticals Inc. (FENC) Among the 13 names with a forward estimate, 3 sit above both the valuation and growth reference points. The position combines operating momentum with market confidence, but durability still needs to hold beyond the forecast. Premium Without Faster Growth Above-median multiple · below-median revenue growth 4 names Merck & Co., Inc. (MRK) · Novartis AG (NVS) · Elanco Animal Health Incorporated (ELAN) · +1 more Among the 13 names with a forward estimate, 4 carry above-reference valuations despite below-reference growth. Their standing is associated with factors beyond near-term expansion, including portfolio durability and earnings visibility. Growth Awaiting Recognition Below-median multiple · above-median revenue growth 4 names Supernus Pharmaceuticals, Inc. (SUPN) · Phibro Animal Health Corporation (PAHC) · ANI Pharmaceuticals, Inc. (ANIP) · +1 more Among the 13 names with a forward estimate, 4 deliver above-reference growth while trading below the valuation reference. The strategic question is whether product mix, concentration or earnings quality limits recognition. Pressure on Both Measures Below-median multiple · below-median revenue growth 2 names Pfizer Inc. (PFE) · Organon & Co. (OGN) Among the 13 names with a forward estimate, 2 sit below both reference points. Portfolio renewal, cost structure and exposure to loss of exclusivity become central operating questions.

  11. 11
    03 · GROWTH VS PROFITABILITY

    Few Names Clear Both Growth and Margin, and They Do Not Sit at the Top of the Range

    This slide plots 12 companies with both growth and margin estimates against P/E (CY2027E) by quadrant.

    We plot the companies with both growth and margin estimates against their P/E (CY2027E), cutting at the covered medians of 7% growth and 30% margin. Very few names clear both bars at once, and the ones that do do not sit at the top of the pricing range. That scarcity is itself informative: balanced operating performance is rare in this sector, so we treat it as a distinguishing signal rather than the norm.

    Everything on this page

    03 · GROWTH VS PROFITABILITY Few Names Clear Both Growth and Margin, and They Do Not Sit at the Top of the Range Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2027E, y-axis) · 12 companies with both estimates · cuts at the covered medians (7% growth, 30% margin) · median P/E per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful P/E (balanced n=2; margin-only n=4; growth-only n=4; neither n=2). Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 0% 20% 40% 60% 10% 20% 30% 40% 50% MARGIN ONLY median 12.5x BALANCED median 18.8x NEITHER median 38.3x GROWTH ONLY median 9.6x PFE OGN MRK ELAN ALKS NVS JNJ ABBV ANIP PAHC SUPN PHAT x: revenue growth (CY2027E) · y: EBITDA margin (CY2027E) HOW TO READ THIS Across the 12 names with growth and margin data, 2 clear both the 7% growth bar and the 30% margin bar. That cell is priced at 18.8x, compared with 38.3x for the 2 names below both bars. The 4 margin-only names are priced at 12.5x, while the 4 growth-only names are priced at 9.6x. Johnson & Johnson (JNJ) and AbbVie Inc. (ABBV) are the names above both bars. The neither median rests on 2 names and is lifted by ALKS at 59.0x. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 6 of 12 names clear it (JNJ, ABBV, MRK, NVS, SUPN, PHAT).

  12. 12
    03 · THE AGENDA

    Doubts About Growth Point to Revenue Mix; Doubts About Margin Point to Cost Structure

    This slide frames the open questions on revenue mix and cost structure that the growth and margin data raise.

    We translate the growth and margin cohort data into the specific questions an owner or acquirer should resolve next. Doubts about growth point toward revenue mix, while doubts about margin point toward cost structure. This is our directional advisory judgment grounded in the data shown earlier, not investment advice, so we frame it as an agenda for management to work through rather than a verdict.

    Everything on this page

    03 · THE AGENDA Doubts About Growth Point to Revenue Mix; Doubts About Margin Point to Cost Structure NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Can the Earnings Base Outlast the Patent Cliff? Test portfolio concentration, remaining exclusivity and replacement capacity against the earnings expected beyond the current forecast. What changes the answer: The answer changes when a lead product approaches loss of exclusivity without replacement revenue. Can Growth Convert into Durable Profit? Examine whether growth carries repeatable net pricing, payer access and an economic path through gross-to-net pressure. What changes the answer: The answer changes when prescription momentum fails to translate into sustained net revenue and margin. Should the Portfolio Be Built or Supplemented? Compare internal pipeline timing with partnership and acquisition routes where therapeutic fit and commercial infrastructure are clear. What changes the answer: The answer changes when internal replacement timing falls behind the exclusivity schedule. Can the Cost Base Hold Through Change? Assess manufacturing utilization, supply resilience and commercial spending against the product mix expected after portfolio transitions. What changes the answer: The answer changes when volume, mix or regulatory constraints weaken fixed-cost absorption.

  13. 13
    SECTION 04

    04

    This is a section divider introducing the precedent transaction analysis.

    We turn now to how precedent transactions have rewarded different forms of certainty. The transaction record spans established brands, commercial assets and manufacturing platforms.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Precedent Transactions Reward Different Forms of Certainty The transaction record spans established brands, commercial assets and manufacturing platforms. 04 of 06 Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13

  14. 14
    04 · DEAL CASE STUDIES

    Transaction Pricing Moves with Asset Type and Earnings Visibility

    This slide walks through select case studies from the transactions with disclosed terms.

    We walk through select case studies drawn from the transactions with disclosed terms, using multiples on LTM financials at announcement where disclosed. These deal multiples sit on a different basis than our CY2027E public-market lens, so we draw no spread between the two. What the case studies show is that pricing moves with asset type and earnings visibility, so the same logic that separates public valuations also separates deal outcomes.

    Everything on this page

    04 · DEAL CASE STUDIES Transaction Pricing Moves with Asset Type and Earnings Visibility 1 of 14 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 50 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate filings collapsed; duplicate precedent id); figures are shown as recorded in the filing. 17 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Oct-2022 $2.9B Sumitovant Biopharma Ltd. Sumitovant Biopharma Ltd. paired with Myovant Sciences Ltd. in an announced pharmaceutical transaction. EV / LTM revenue 0.7x EV / LTM EBITDA 8.8x WHY THE DEAL HAPPENED The transaction suggests strategic value in combining a biopharma owner with a pharmaceutical development and commercial platform. The pairing is consistent with sector buyers seeking closer ownership of product economics and execution. HOW THE TARGET WAS VALUED The disclosed value was $2.9B, with pricing at 0.7x revenue and 8.8x EBITDA. The revenue multiple sits at the low end of disclosed revenue precedents, while the EBITDA multiple is below several disclosed EBITDA outcomes in the set.

  15. 15
    SECTION 05

    05

    This is a section divider introducing the strategic implications section.

    We close the analysis by asking what durability requires operationally. Portfolio mix, exclusivity planning and commercial execution shape the strategic agenda ahead.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS Durability Must Be Built into the Earnings Base Portfolio mix, exclusivity planning and commercial execution shape the strategic agenda. 05 of 06 Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15

  16. 16
    05 · STRATEGIC IMPLICATIONS

    Earnings Visibility Is Associated with Where Owners Sit in the Pricing Range

    This slide sets out directional questions for owners, management teams and boards tied to earnings visibility.

    We frame earnings visibility as something associated with where a company sits in the pricing range, not a guarantee. For owners, the priority is protecting the durable earnings base against loss of exclusivity. For management teams, it is converting demand into repeatable economics, and for boards, it is matching capital to portfolio timing, so each audience leaves with a distinct, actionable next question.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Earnings Visibility Is Associated with Where Owners Sit in the Pricing Range NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Protect the Durable Earnings Base Prioritize portfolio mix, lifecycle management and replacement capacity where loss of exclusivity can narrow the earnings runway. FOR MANAGEMENT TEAMS Turn Demand into Repeatable Economics Focus on formulary access, prior-authorization conversion, persistency and gross-to-net discipline where growth has yet to earn stronger market standing. FOR BOARDS Match Capital to Portfolio Timing Frame build-versus-buy decisions around exclusivity schedules, pipeline maturity, financing capacity and the time required to establish commercial traction.

  17. 17
    SECTION 06

    06

    This is a section divider introducing the full comparables universe, methodology and sources.

    We close with the full universe, the methodology and the source index behind every figure in this report. This section exists so any number here can be traced back to its origin.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17

  18. 18
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on P / E (CY2027E), Grouped by Valuation Tier

    This slide lists all 13 rated companies on P/E (CY2027E), grouped by valuation tier, alongside 8 unrated names.

    We list all 13 rated companies on P/E (CY2027E), shaded above or below the sector median of 11.6x, alongside the names that carry no eligible multiple. Every rated row here also sits in the companion workbook with the complete field set. This table is the primary-source check for every multiple used earlier in the deck, so a client can trace any figure back to its rated company.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on P / E (CY2027E), Grouped by Valuation Tier Teal shading marks a P/E above the sector median (11.6x); amber marks below · 13 rated companies; 8 not rated (no eligible P/E) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 13 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV P/E (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥16.3x · median 21.4x · 3 companies Alkermes plc ALKS Specialty branded and generic manufacturers $7.8B 59.0x 6% 11% 17 Johnson & Johnson JNJ Diversified branded pharmaceutical majors $688B 21.4x 7% 38% 46 Elanco Animal Health Incorporated ELAN Specialty branded and generic manufacturers $14.8B 17.6x 5% 21% 26 CORE — 9.8x–16.3x · median 11.6x · 7 companies AbbVie Inc. ABBV Diversified branded pharmaceutical majors $534B 16.3x 9% 51% 60 Merck & Co., Inc. MRK Diversified branded pharmaceutical majors $411B 15.6x 5% 47% 52 Novartis AG NVS Diversified branded pharmaceutical majors $321B 15.0x 7% 41% 48 Fennec Pharmaceuticals Inc. FENC Development-stage novel therapeutics $338M 11.6x 42% n/a n/a Supernus Pharmaceuticals, Inc. SUPN Specialty branded and generic manufacturers $2.2B 10.0x 56% 20% 76 Pfizer Inc. PFE Diversified branded pharmaceutical majors $219B 9.9x -4% 39% 35 Phibro Animal Health Corporation PAHC Specialty branded and generic manufacturers $2.2B 9.9x 12% 16% 28 DISCOUNT — <9.8x · median 7.1x · 3 companies Phathom Pharmaceuticals, Inc. PHAT Development-stage novel therapeutics $569M 9.4x 57% 29% 86 ANI Pharmaceuticals, Inc. ANIP Specialty branded and generic manufacturers $2.0B 7.1x 12% 26% 38 Organon & Co. OGN Diversified branded pharmaceutical majors $11.1B 3.8x 4% 31% 35

  19. 19
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This slide lists precedent transactions with disclosed terms, newest first.

    We list the transactions with disclosed terms, newest first, with deal values linking to the underlying filing. These multiples sit on an LTM-at-announcement basis and are not directly comparable to our CY2027E public-market figures. This is the primary-source record behind the deal commentary earlier in the deck, so a client can verify every transaction cited.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 14 transactions with disclosed terms in this tier (31 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 50 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate filings collapsed; duplicate precedent id); figures are shown as recorded in the filing. 17 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Apr-2025 KKR & Co. Inc. → Karo Pharma AB n/a 0.7x 14.0x KKR & Co. Inc. and Karo Pharma AB were announced at 0.7x revenue and 14.0x EBITDA, placing disclosed pricing alongside an established-brand target. Oct-2022 Sumitovant Biopharma Ltd. → Myovant Sciences Ltd. $2.9B 0.7x 8.8x Sumitovant Biopharma Ltd. and Myovant Sciences Ltd. show a biopharma buyer pairing with a pharmaceutical target. Jun-2022 Gurnet Point Capital / Patient Square Capital → Radius Health, Inc. n/a 3.2x n/a Gurnet Point Capital / Patient Square Capital and Radius Health, Inc. were announced at 3.2x revenue. Sep-2019 Swedish Orphan Biovitrum AB → Dova Pharmaceuticals, Inc. n/a 3.0x n/a Swedish Orphan Biovitrum AB and Dova Pharmaceuticals, Inc. were announced at 3.0x revenue. May-2019 AmpliPhi Biosciences Corporation → C3J Therapeutics, Inc. n/a 0.7x 8.8x AmpliPhi Biosciences Corporation and C3J Therapeutics, Inc. were announced with disclosed revenue and EBITDA pricing. Jan-2019 Strides Pharma Science Limited → Vensun Pharmaceuticals, Inc. n/a 1.1x n/a Strides Pharma Science Limited and Vensun Pharmaceuticals, Inc. were announced at 1.1x revenue. Jul-2018 Cambrex Corporation → Halo Pharmaceutical, Inc. n/a n/a 15.7x Cambrex Corporation and Halo Pharmaceutical, Inc. were announced at 15.7x EBITDA. Sep-2016 Horizon Therapeutics → Raptor Pharmaceuticals n/a 3.7x n/a Horizon Therapeutics and Raptor Pharmaceuticals were announced at 3.7x revenue. May-2015 AMRI Global → Prime European Therapeuticals S.p.A. n/a n/a 13.3x AMRI Global and Prime European Therapeuticals S.p.A. were announced at 13.3x EBITDA.

  20. 20
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This slide continues the list of precedent transactions with disclosed terms, newest first.

    We continue the transaction list here, maintaining the same newest-first order and LTM-at-announcement basis. Data-quality flags are noted where a record carries an unresolved deal-value unit or a collapsed duplicate filing. Together with the prior page, this is the complete disclosed-terms record behind the deal analysis, so nothing in the earlier commentary rests on an unlisted transaction.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 14 transactions with disclosed terms in this tier (31 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 50 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate filings collapsed; duplicate precedent id); figures are shown as recorded in the filing. 17 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Sep-2014 Consort Medical plc → Aesica Pharmaceuticals Limited n/a n/a 11.5x Oct-2011 Hellman & Friedman LLC and The Carlyle Group Inc. → Pharmaceutical Product Development, Inc. n/a n/a 10.2x Apr-2011 Merck → Inspire Pharmaceuticals n/a 3.3x n/a n/a December 2021 → Pfizer Inc n/a 0.7x 8.8x n/a Auxilium Pharmaceuticals, LLC → Actient Pharmaceuticals, LLC n/a 5.5x n/a Value shown as recorded in the filing; deal value unit unresolved, status defaulted announced.

  21. 21
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This slide explains the report's sources, assumptions and data-quality treatment.

    We set out here exactly how this report was built: what was included, what was excluded and where every underlying disclosure lives. Every figure in this report links to the record it was taken from, and where it doesn't, this page names the source and the basis on which it was read. This is the page to return to whenever a client wants to understand why a number is or isn't on the page.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice 21 VALUATION BASIS Primary valuation basis: P / E on CY2027E consensus (13 of 21 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on P / E rather than EV / EBITDA; validated coverage supports the industry standard (13 of 21 companies), so this report follows it. P / E on CY2027E is the lead convention: it is the sector-appropriate prior for Pharmaceuticals and it clears the coverage gate with 13 of 21 companies (62%). EV / Revenue is carried as a cross-check. DATA QUALITY & EXCLUSIONS 50 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 650 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (649) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  22. 22

    In This Peer Set, the Premium Sits with Confidence That Earnings Can Endure.

    This is the closing slide restating that the premium sits with confidence that earnings can endure.

    In this peer set, the premium sits with confidence that earnings can endure. The companion tables carry the full universe, the exclusion ledger and the complete source index for any figure a client wants to trace.

    Everything on this page

    In This Peer Set, the Premium Sits with Confidence That Earnings Can Endure. NeuraCap AI — Pharmaceuticals Coverage September 2026 · Prepared by NeuraCap AI · Confidential Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 22

Sources and methodology

This report covers Pharmaceuticals (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Pharmaceuticals) with market data and consensus estimates as of September 28, 2026. The company universe is the 21 listed companies whose core business is Pharmaceuticals according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: AbbVie Inc. (ABBV), Alkermes plc (ALKS), ANI Pharmaceuticals, Inc. (ANIP), BioAge Labs Inc. (BIOA), Design Therapeutics, Inc. (DSGN), Elanco Animal Health Incorporated (ELAN), Fortress Biotech, Inc. (FBIO), Fennec Pharmaceuticals Inc. (FENC), Grifols, S.A. (GRFS), Disc Medicine, Inc. (IRON), Johnson & Johnson (JNJ), LENZ Therapeutics, Inc. (LENZ), Merck & Co., Inc. (MRK), Novartis AG (NVS), Organon & Co. (OGN), Phibro Animal Health Corporation (PAHC), Pfizer Inc. (PFE), Phathom Pharmaceuticals, Inc. (PHAT), Pliant Therapeutics, Inc. (PLRX), Sanofi (SNY), Supernus Pharmaceuticals, Inc. (SUPN). The market map groups them by business vertical — Diversified branded pharmaceutical majors: 8 companies (JNJ, ABBV, MRK, NVS, PFE, SNY, GRFS, OGN); Development-stage novel therapeutics: 8 companies (IRON, PHAT, DSGN, FENC, BIOA, FBIO, LENZ, PLRX); Specialty branded and generic manufacturers: 5 companies (ELAN, ALKS, SUPN, PAHC, ANIP). 13 of the 21 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Pharmaceuticals (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Pharmaceuticals) with market data and consensus estimates as of September 28, 2026. The company universe is the 21 listed companies whose core business is Pharmaceuticals according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: AbbVie Inc. (ABBV), Alkermes plc (ALKS), ANI Pharmaceuticals, Inc. (ANIP), BioAge Labs Inc. (BIOA), Design Therapeutics, Inc. (DSGN), Elanco Animal Health Incorporated (ELAN), Fortress Biotech, Inc. (FBIO), Fennec Pharmaceuticals Inc. (FENC), Grifols, S.A. (GRFS), Disc Medicine, Inc. (IRON), Johnson & Johnson (JNJ), LENZ Therapeutics, Inc. (LENZ), Merck & Co., Inc. (MRK), Novartis AG (NVS), Organon & Co. (OGN), Phibro Animal Health Corporation (PAHC), Pfizer Inc. (PFE), Phathom Pharmaceuticals, Inc. (PHAT), Pliant Therapeutics, Inc. (PLRX), Sanofi (SNY), Supernus Pharmaceuticals, Inc. (SUPN). The market map groups them by business vertical — Diversified branded pharmaceutical majors: 8 companies (JNJ, ABBV, MRK, NVS, PFE, SNY, GRFS, OGN); Development-stage novel therapeutics: 8 companies (IRON, PHAT, DSGN, FENC, BIOA, FBIO, LENZ, PLRX); Specialty branded and generic manufacturers: 5 companies (ELAN, ALKS, SUPN, PAHC, ANIP). 13 of the 21 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

50 records failed a validation gate and never feed a statistic in this report (44 excluded from aggregate; 6 quarantined). Each exclusion, with its reason: ALKS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BIOA — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BIOA — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BIOA — Implied EBITDA margin -1700.2% outside the plausible band [-100%, 80%] (effect: quarantined) · BIOA — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BIOA — Implied EBITDA margin -723.8% outside the plausible band [-100%, 80%] (effect: quarantined) · BIOA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BIOA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BIOA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BIOA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DSGN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DSGN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DSGN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DSGN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ELAN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · FBIO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · FBIO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · FBIO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · FBIO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · FBIO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · FENC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · FENC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · IRON — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · IRON — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · IRON — Implied EBITDA margin -8943.4% outside the plausible band [-100%, 80%] (effect: quarantined) · further items are listed in the companion tables.

Primary valuation basis and how it was chosen

Primary valuation basis: P / E on CY2027E consensus (13 of 21 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on P / E rather than EV / EBITDA; validated coverage supports the industry standard (13 of 21 companies), so this report follows it. P / E on CY2027E is the lead convention: it is the sector-appropriate prior for Pharmaceuticals and it clears the coverage gate with 13 of 21 companies (62%). EV / Revenue is carried as a cross-check. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 14 of 21 companies; EV / rEVenue: 20 of 21 companies; P/E: 13 of 21 companies. 1 company shows a non-meaningful EV / EBITDA denominator and is excluded from that statistic. 6 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥16.3x, Core 9.8x–16.3x, Discount <9.8x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 11.6x = median(pe_ratio CY2027E) (13 rated companies) · 21.4x = median(pe_ratio CY2027E) within Premium tier (n=3) · 11.6x = median(pe_ratio CY2027E) within Core tier (n=7) · 7.1x = median(pe_ratio CY2027E) within Discount tier (n=3) · 10.0x = median(pe_ratio CY2027E) | growth ≥ 7% (n=7) · 15.3x = median(pe_ratio CY2027E) | growth < 7% (n=6) · 15.3x = median(pe_ratio CY2027E) | EBITDA margin ≥ 30% (n=6) · 9.9x = median(pe_ratio CY2027E) | EBITDA margin < 30% (n=6) · 42% = median Rule of 40 score (revenue growth + EBITDA margin) (n=12) · 18.8x = median(pe_ratio CY2027E) within balanced quadrant (n=2) · 12.5x = median(pe_ratio CY2027E) within marginOnly quadrant (n=4) · 9.6x = median(pe_ratio CY2027E) within growthOnly quadrant (n=4) · 38.3x = median(pe_ratio CY2027E) within neither quadrant (n=2) · 59.0x = pe_ratio CY2027E for ALKS (quadrant outlier)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Pharmaceuticals recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 31 transactions were recorded for this industry; 14 are shown. 17 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 32 × no evidence record; 14 × deal value unit unresolved; 3 × duplicate precedent id; 1 × duplicate filings collapsed. Case studies lead with the 1 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 654 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Pharmaceuticals?

Company valuation reports run the same method against a single business — public or private.